Abstract The scavenger receptor class B type 1 (SCARB1) gene is a key component in the reverse cholesterol transport pathway and thus plays an important role in lipid metabolism. Studies suggest that the SCARB1 gene may contribute to variation in plasma lipid levels at fasting; however, the results have been inconsistent, and it is unclear whether SCARB1 may also influence lipid response to dietary and pharmacologic interventions. In this study, we examined genetic variation in the SCARB1 gene in participants of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study for associations with basal lipid levels, changes in lipid measures after dietary fat intake, and fenofibrate treatment. We found that the exon 1 variant SCARB1_G2S was significantly associated with postfenofibrate change for triglycerides (TG) (P = 0.004). Subjects bearing SCARB1_G2S minor allele A tend to have higher responsiveness to fenofibrate in lowering TG. In summary, our study suggested that the SCARB1 gene may serve as a useful marker that predicts variation in baseline lipid levels, postprandial lipid response, and response to fenofibrate intervention.
1997). High-density lipoprotein cholesterol (HDL-C) levels inversely correlated with CHD risk, suggesting HDL-C protects against atherosclerosis (Gordon and Rifkind 1989; Uiterwaal et al. 1994 ). TGs, low-density lipoprotein (LDL) and HDL particles and particle sizes are highly reproducible and are sensitive to dietary manipulation and lipidlowering drugs (Tsai et al. 1992; Yuan et al. 1994) . Studies showed that both fasting lipid levels and postprandial lipid response are modulated by genetic factors (Mero et al. 1998; Ordovas 2001) . In addition, several lines of evidence suggest that lipid response to pharmacological interventions is highly variable and has genetic control (Suter et al. 2001; Durstine et al. 2001; Kuller et al. 2001) . However, these underlying genetic factors are largely unknown.
The scavenger receptor class B type 1 (SCARB1) gene is the first reported HDL receptor (Acton et al. 1996) . SCARB1 mediates selective uptake of HDL-C without degradation of entire HDL particles (Acton et al. 1996) . Overexpression of SCARB1 in mice resulted in dramatic reductions in plasma HDL-C concentrations (Kozarsky et al. 1997) . Conversely, suppression of SCARB1 expression was related to a marked increase in plasma HDL-C, characterized by enlarged cholesterol-rich HDL particles and impaired HDL-C clearance . As a multilipoprotein receptor, SCARB1 also regulates the concentrations of LDL-C and very-low-density lipoprotein (VLDL) (Acton et al. 1996; Ueda et al. 1999) . Interestingly, SCARB1 is likely to be involved in intestinal absorption of TGs (Hauser et al. 1998) . Importantly, the SCARB1 gene is located on chromosome 12q24, a region showing significant linkage to plasma HDL-C and TG levels (Feitosa et al. 2005) . Several previous studies also reported associations between the SCARB1 gene polymorphisms and plasma cholesterol levels in humans; however, the results have been inconsistent (Acton et al. 1999) and it is unclear whether the SCARB1 gene is involved in modulating postprandial lipid response and response to pharmacological interventions.
Stimulated by the importance of SCARB1 in lipid metabolism, we systemically investigated whether the SCARB1 gene contributes to baseline lipid levels, lipid response to dietary fat challenge, and, for the first time, TG-lowering drug therapy in participants of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study.
Materials and methods

Study population
Our study population came from the GOLDN study (http://www.biostat.wustl.edu/goldn/). The participants of GOLDN study were mainly rerecruited from two National Heart, Lung, and Blood Institute Family Heart Study (FHS) field centers: Minneapolis, MN, and Salt Lake City, UT. Nearly all subjects were of European ancestry. Eligibility criteria were: (1) C18 years of age, (2) fasting TGs \1,500 mg/dl, (3) willing to participate in the study and attend the scheduled clinic exams, (4) member of a family with at least two members in a sibship, (5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) results within normal range, and (6) creatinine B2.0 mg/dl. Exclusion criteria were: (1) history of liver, kidney, pancreas, or gall bladder disease or malabsorption, (2) current pregnancy, (3) insulin use, (4) use of lipid-lowering drugs (including prescription, over the counter, and nutriceuticals; volunteers taking these agents were withdrawn from them at least 4 weeks prior to the study with physician's approval) (5) use of warfarin, (6) women of childbearing potential not using an acceptable form of contraception, (7) known hypersensitivity to fenofibrate, and (8) history of pancreatitis within 12 months prior to enrollment.
Our previous studies demonstrated that Caucasians in Utah and Minnesota were homogeneous and thus pooling data across centers would not threaten the validity of this study (Pankow et al. 2002) .
Dietary and pharmacological interventions
All family members underwent a baseline screening visit (visit 0). Eligible subjects were asked to participate in a clinical examination with dietary fat intake and the fenofibrate trial. The dietary fat challenge was conducted to assess baseline and postprandial TGs and related phenotypes. The fat challenge consisted of eating a test meal during a 15-min period and returning to the clinic 3.5 and 6 h later to collect blood samples. The caloric intake of the intervention meal was determined by body surface area. The meal derived 83% of calories from fat and contained 700 calories per meter squared of body surface area. We measured total TGs, TG in chylomicrons, VLDL and TG remnant particles, HDL and LDL particle sizes, total cholesterol, LDL-C, and HDL-C at baseline and at 3.5 and 6 h after consumption of the meal.
This fat challenge was done twice, once while participants were taking no lipid-lowering medications and once while taking fenofibrate. The fenofibrate intervention consisted of a 3-week treatment period in which participants took oral fenofibrate 160 mg tablets once daily. We measured lipids twice after a minimum fast of 10 h on the last 2 days of the treatment period (visits 3 and 4). The intervention procedure is displayed in supplementary data ( Supplementary Fig. 1, ESM) .
Plasma lipid and lipoprotein measurements
Fasting, 3.5, and 6 h postprandial lipoprotein samples were centrifuged within 20 min of collection at 2,000 g for 15 min at 4°C. Plasma samples of each participant were stored at 4°C until completion of the treatment period. All samples from a single participant were analyzed within the same batch. TGs were measured using a glycerol blanked enzymatic method (Trig/GB, Roche Diagnostics Corporation, Indianapolis, IN, USA) on the Roche/Hitachi 911 Automatic Analyzer (Roche). Cholesterol was measured on the Hitachi 911 using a cholesterol esterase-cholesterol oxidase reaction (Chol R1, Roche). The same reaction was also used to measure HDL-C after precipitation of non-HDL-C with magnesium/dextran. LDL-C was measured by a homogeneous direct method (LDL Direct Liquid Select TM Cholesterol Reagent, Equal Diagnostics, Exton, PA, USA) on the Hitachi 911. TGs were measured at all time points, i.e., 0, 3.5, and 6 h before and after fenofibrate trial. HDL-C and LDL-C were only measured at baseline before and after fenofibrate exposure.
Plasma lipoprotein particles and subclass distributions were determined by proton nuclear magnetic resonance (NMR) spectroscopy as previously described (Ordovas et al. 2000; Otvos et al. 1992) . Each profile displayed the concentrations of three VLDL, one IDL, three LDL, and three HDL subclasses and the weighted-average particle sizes of VLDL, LDL, and HDL. The lipoprotein subclass categories used were large LDL (21.3-27.0 nm), intermediate LDL (19.8-21 .2), small LDL (18.3-19.7 nm), large HDL (8.8-13.0 nm), intermediate , and small HDL (7.3-7.7 nm). Levels of LDL and HDL subclasses are expressed in nanomole units of cholesterol. LDL and HDL subclass distributions determined by gradient gel electrophoresis and NMR have been shown to be closely correlated (Otvos et al. 1992) . HDL, LDL, and VLDL particles and subclass were measured at all time points (0, 3.5, and 6 h) before and after fenofibrate trial.
SNP selection and genotyping
Single nucleotide polymorphisms (SNPs) were identified by searching public databases such as the Single Nucleotide Polymorphism Database (dbSNP) (http://www.ncbi. nlm.nih.gov/SNP/). We selected seven SNPs at the SCARB1 gene locus based on the following criteria in order of importance in our selection scheme: (1) validation status, (2) functional relevance and importance, (3) degree of heterozygosity, i.e., minor allele frequencies (MAF) [0.0, and (4) previous evidence of association with lipid measurements.
SNPs were genotyped using the 5 0 nuclease allelic discrimination Taqman assay with allelic-specific probes on the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to standard laboratory protocols. We used GRR software (Abecasis et al. 2001 ) to detect pedigree errors by graphically inspecting the distribution for marker allele sharing among pairs of family members or all pairs of individuals. The SNP allele frequencies were estimated via a maximum-likelihood method (Boehnke 1991) . For each SNP, a v 2 test was used to examine deviation of SNP genotypes from Hardy-Weinberg equilibrium (HWE) (Fisher 1934) . The overall genotyping error and missing rate was *1%.
Statistical analyses
Pairwise linkage disequilibrium (LD) between SNPs was calculated using the normalized measure, Lewontin's D, (Lewontin 1964) , using the publicly available Haploview version 3.3 software (Barrett et al. 2005) . Normality for continuous variables was checked. After logarithmic transformations for TGs, HDL-C, and HDL particle size, they approximately follow normal distribution.
Associations were tested between the SCARB1 SNPs and a number of lipid profiles, which included: (1) baseline lipid levels (including TGs, HDL-C, LDL-C, HDL, and LDL particles and particle sizes), (2) changes of lipid profile between pre-and postfenofibrate treatments, (3) changes of lipid profile at 0-3.5 h (which, biologically, represents the absorption phase of TGs after a fat meal), and (4) changes of lipid profile at 3.5-6 h (which, biologically, represents the clearance phase of TGs after a fat meal).
Genotype-phenotype association analyses were performed using a linear mixed model implemented in SAS (version 9.1, SAS Institute, Cary, NC, USA). In the model, genotypes were treated as fixed effects, and the dependencies among members within each family were treated as random effects. Age, age 2 , age 3 , gender, and field center were included as covariates. The model can be defined as:
where y it is the phenotype of individual i measured at time point t; a and b are the intercept and slope for the population level effects (fixed effects), respectively, and c ia and c ib are for the individual level effects (random effects), respectively, and e it is the residual. The model was implemented in the PROC MIXED procedure in SAS. As the growth curve slope (b + c ib ) eliminates the noise e it , it represents an accurate and stable estimate of lipid changes.
Haplotypes were reconstructed based on the seven SNPs. The software MERLIN version 1.0.1 (Abecasis et al. 2002) was used for haplotype inference. MERLIN can accommodate LD between SNPs in haplotype inference (Abecasis and Wigginton 2005) . Association analysis for haplotypes was conducted using a mixed model similar to that for single SNPs. In addition, a global test was performed to examine whether phenotype differences existed among all haplotypes simultaneously.
Results
Study population
Characteristics of the study subjects are shown in Table 1 . A total of 1,327 subjects (639 men and 688 women) from 148 families were genotyped. Of these 1,327 subjects, 861 subjects (427 men and 434 women) went through the fenofibrate trial and had complete lipid phenotype (TGs, HDL-C, and LDL-C) and genotype data. Men ranged in age from 18.0 to 87.6 (50.6 ± 15.9) years, and women ranged from 18.0 to 87.2 (51.1 ± 15.8) years. For both men and women at all the time points, TG, LDL-C, and LDL particles after fenofibrate treatment were significantly lower than those before fenofibrate treatment (P \ 0.001). Conversely, HDL-C and HDL particles after fenofibrate treatment were significantly higher than those before fenofibrate treatment (P \ 0.001). Postfenofibrate HDL sizes generally increased compared with those before fenofibrate Association analyses for single SNPs Table 2 summarizes the association results between SNPs and lipid response to fenofibrate treatment in the total sample. Overall, fenofibrate was associated with a 27.2 mg/dl reduction in TG level. The SNP SCARB1_G2S was associated with fenofibrate response for both TG (P = 0.004) and HDL-C (P = 0.01). The SNP SCARB1_I82699 was associated with fenofibrate response for TG (P = 0.02). Figure 1 displays the changes of HDL-C and TG for SCARB1_G2S genotypes. It can be seen that subjects bearing allele A had larger changes for both HDL-C and TG, suggesting higher response to fenofibrate treatment by increasing plasma HDL-C level and lowering TG level. Table 3 summarizes association results of lipid measures at baseline (0 h) and lipid changes across time points of 0-3.5 h (0/3.5) and 3.5-6 h (3.5/6). The most pronounced association was found for SNP SCARB1_G2S. In the prefenofibrate phase, a significant association was found between SCARB1_G2S and baseline HDL (P = 0.001), HDL 0-3.5 (P = 0.04), and changes of HDL particle size at time period 0-3.5 h (P = 0.03). SCARB1_G2S also showed associations with baseline TG (P = 0.004), TG 0-3.5 (P = 0.005), and baseline LDL (P = 0.03) (Table 3) .
For postfenofibrate lipid measures, significant associations were observed for SCARB1_G2S with baseline HDL particles (P = 0.002), HDL 3.5-6 , and HDL size at time period 3.5-6 h (P = 0.0002). However, no association was found between SCARB1_G2S and baseline TG or TG response to fat loading.
Association analyses for haplotypes
A total of 51 haplotypes was observed in our family data. To maximize the statistical power and minimize potential bias caused by the small number of subjects bearing a specific haplotype, we only tested associations between common haplotypes (allele frequencies C0.05) and lipid measures. Table 4 illustrates the frequencies and association information of the six common haplotypes (H1-H6). No significant association was observed between any single haplotype with response to fenofibrate treatment. However, haplotype H1 showed significant association with prefenofibrate baseline HDL (P = 0.002) and marginal association with HDL 3.5-6 (P = 0.07). H1 was also association with prefenofibrate TG 0-3.5 (P = 0.02). Haplotype H2 was associated with postfenofibrate HDL 3.5-6 and HDL size 3.5-6 . Other haplotypes not specified here showed no significantly association with any lipid phenotypes.
Discussion
In this study, we systemically investigated the relationship between the SCARB1 gene and lipid profiles at the baseline and postprandial states, as well as lipid lowering treatment. Dietary fat challenges and pharmacologic intervention are two potent stimuli that produce large but highly variable changes in lipid profile (Suter et al. 2001; Durstine et al. 2001; Kuller et al. 2001) . We undertook two interventions (i.e., dietary fat challenge and pharmacologic intervention), because by studying contexts that affect both axes (i.e., increasing and decreasing TGs) we may gain novel insight into underlying mechanisms by which the SCARB1 gene may regulate lipids. The most interesting finding was with the SNP SCARB1_G2S. Allele A of this SNP, compared with the alternative allele G, was associated with a higher response to fenofibrate by lowering TG levels and increasing plasma HDL-C levels (but the significance with HDL-C disappeared after adjusting for multiple testing). Several previous studies examined association between the SCARB1 gene polymorphisms and lipid measures in different human populations. In a white population, male carriers of the two allele (1/2) of SCARB1_G2S had increased HDL-C and reduced LDL-C and TGs concentrations at baseline (Acton et al. 1999) . In a dietary intervention study, carriers of this allele appeared to be more responsive to changes in dietary saturated fat intake, as they exhibited a greater increase in LDL-C compared with 1/1 individuals (Pérez-Martínez et al. 2003) . In the Framingham Study, diabetic subjects carrying the SCARB1_G2S A allele had significantly lower LDL-C and HDL-C concentrations (Osgood et al. 2003) . Our results reported here are in agreement with these earlier findings. An important extension of our study is that we, for the first time, found the SCARB1 gene is also related to lipid response to pharmacological (fenofibrate) treatment.
Mice studies showed that the genetic expression of SCARB1 modifies the metabolism of HDL-C. Overexpression of SCARB1 in the liver lowers plasma values for HDL-C and increases the concentration and biliary secretion of cholesterol (Kozarsky et al. 1997; Wang et al. 1998) . In contrast, the total suppression of its expression increases plasma HDL-C and lowers cholesterol content in bile and the suprarenal gland. After feeding them a meal containing [
14 C] cholesterol and [ 3 H] triolein, mice with SCARB1 overexpression primarily in the intestine presented a rise in intestinal absorption of both lipids, which was not due to a defect in chylomicron clearance nor to a change in bile flow or bile acid content (Bietrix et al. 2006) , suggesting that SCARB1 acts as a multiligand SNP single nucleotide polymorphism, HDL high-density lipoprotein, LDL low-density lipoprotein, VLDL very-low-density lipoprotein P values of association tests using linear mixed models. Associations were tested for lipid measures at baseline, and changes of lipid measures over time 0-3.5 (0/3.5) h and 3.5-6 (3.5/6) h for pre-fenofibrate and postfenofibrate, separately. P values of B0.05 are in bold transporter in the small intestine and is responsible for the accelerated uptake of cholesterol and TG hydrolysis products. The mechanism by which SCARB1 delivers cholesterol esters to cells is not well understood, but it appears to be different from the well-characterized LDL receptor endocytic pathway (Brown and Goldstein 1986) . It is likely that SCARB1 mediates uptake of lipids from both LDL and HDL, and this uptake is associated with an increase in cholesterol esterification (Stangl et al. 1998 ).
The physiological mechanism of SCARB1 in the postprandial lipemic response and pharmacologic intervention awaits further molecular/physiological studies for elucidation. Nonetheless, our findings from this study, along with those of others, suggest a potential mechanism by which SCARB1 gene polymorphisms may be related to a modified hepatic and/or intestinal expression of the SCARB1 gene, through which SCARB1 influences lipid absorption and clearance. In particular, the exon 1 polymorphism of SCARB1_G2S results in an amino acid change in the protein, which may modify receptor activity. Based on the current understanding of this exon 1 variant, it is unlikely that it directly impairs selective cholesterol uptake. This is because selective cholesterol uptake resides primarily in the extracellular domain of the receptor, but the exon 1 amino acid change occurs in its intracellular N-terminus. Further in vitro and in vivo studies are needed to elucidate the exact functional effects of this SCARB1 exon 1 variant.
A major strength of this study is that participants underwent rigorous interventions of both fat-loading dietary challenge and fenofibrate trial, which provided a valuable resource for investigating the SCARB1 gene regarding its relationship with baseline lipid levels, postprandial lipid response, and response to pharmacological treatment. Despite this asset, our study may have some limitations. First, although multiple SNPs were investigated across the gene, marker density was not sufficient to cover the whole gene. To examine the gene more comprehensively, further studies by testing more SNPs, especially tag SNPs that cover all LDs in SCARB1, should be pursued. Second, a number of tests were performed due to the multiple lipid measures and SNPs involved. After correction for multiple testing, some identified associations only reached nominal significance or even disappeared. For example, the association between SCARB1_G2S and HDL-C in response to fenofibrate treatment turned out to be nonsignificant after adjusting for multiple testing. However, as the tested lipid measures were highly correlated and the tested SNPs were in LD, Bonferroni correction may be too conservative. Third, as our analyses were exploratory, the results await replication studies and eventually functional studies to validate them. Due to the associated high costs and difficulties in compliance with the strict dietary and pharmacological interventions, we currently lack powerful independent data sets (including those from other groups) to replicate our study findings. We will pursue replication/confirmation in future endeavors. In summary, this study suggests that SCARB1 gene polymorphisms may serve as useful markers to predict baseline lipid measures, postprandial lipid response, and fenofibrate response. Our results may have significant clinical implications if confirmed by future studies.
